## **Product** Data Sheet

## AT-0174

Molecular Weight: 189.57

Target: Indoleamine 2,3-Dioxygenase (IDO)

Pathway: Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	AT-0174 is an orally active dual inhibitor of IDO1/TDO2 (tryptophan 2,3-dioxygenase-2) with IC $_{50}$ values of 0.17 and 0.25 $\mu$ M, respectively. AT-0174 has antitumor activity $^{[1][2]}$ .
IC <sub>50</sub> & Target	IDO1 0.17 μM (IC <sub>50</sub> )
In Vitro	AT-0174 (170 mg/kg/day, orally, for 15 days) inhibits tumor growth in non-small cell lung cancer allogeneic mice <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

 $[1]. \ Crump\ LS, et\ al.\ Targeting\ tryptophan\ catabolism\ in\ ovarian\ cancer\ to\ attenuate\ macrophage\ infiltration\ and\ PD-L1\ expression.\ Cancer\ Res\ Commun.\ 2024\ Mar\ 7.$ 

[2]. Crump LS, et al. Targeting tryptophan catabolism in ovarian cancer to attenuate macrophage infiltration and PD-L1 expression. Cancer Res Commun. 2024 Mar 7.

[3]. Wu C, et al. Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer. Cancer Metab. 2023 May 24;11(1):7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA